BC Extra | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

Scientists led by Caltech’s Raymond Deshaies have published a first-in-class proteasome inhibitor that acts through a distinct mechanism from the multiple myeloma drugs Velcade bortezomib and Kyprolis carfilzomib, which could address patients who don't respond...
BioCentury | Apr 15, 2013

De-risking money

De-risking money Cleave Bioscience Inc. 's investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is...
BC Extra | Apr 10, 2013
Financial News

Cleave raises $10M in series A extension

Cancer company Cleave Biosciences Inc. (Burlingame, Calif.) raised $10 million in an extension of a series A round from new investor New Enterprise Associates. The extension brings the total raised by Cleave in the round...
BioCentury | Mar 25, 2013
Emerging Company Profile

Cleave: Proteasome alternatives

Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors....
Items per page:
1 - 4 of 4